Press Releases Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
109.5 ^USD	+1.89%		-0.44%	-11.01%

Apr. 02	Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	MT
Apr. 02	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jazz Pharmaceuticals to Present Data across Growing Oncology Pipeline and Portfolio at ASCO 2024	Apr. 25	AQ
The PharmaMar Group presents financial results for the first quarter of 2024	Apr. 24	AQ
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024	Apr. 17	PR
Jazz Pharmaceuticals : Zanidatamab R&D Day	Mar. 19	PU
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024	Mar. 12	PR
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)	Mar. 07	AQ
Jazz Pharmaceuticals : Corporate Overview	Mar. 01	PU
Jazz: Q4 Earnings Snapshot	Feb. 28	AQ
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance	Feb. 28	PR
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors	Feb. 27	PR
Jazz Pharmaceuticals names new executive vice president and chief financial officer	Feb. 22	AQ
Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024	Feb. 22	AQ
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer	Feb. 21	PR
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences	Feb. 20	PR
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024	Feb. 14	PR
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder	Dec. 22	AQ
Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	Dec. 22	AQ
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 20	PR
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer	Dec. 11	AQ
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting	Dec. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Press Releases

Filters